A broadly cross-reactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Vu, David M ^a   Pajon, Rolando ^a   Reason, Donald C ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; COMPLEMENT; EPITOPE; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; MONOCLONAL ANTIBODY;

ARTICLE; CHEMISTRY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FLOW CYTOMETRY; HUMANS;

EID: 84859753141     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00341     Document Type: Article

References (42)

1. Granoff, D. M. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50 Suppl 2, S54-65 (2010).
2. Sadarangani, M. & Pollard, A. J. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect. Dis. 10, 112-124 (2010).
3. Giuliani, M. M. et al. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103, 10834-10839 (2006). (Pubitemid 44148381)
4. Vu, D. M., Wong, T. T. & Granoff, D. M. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine. 29, 1968-1973 (2011).
5. Snape, M. D. et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29, e71-79 (2010).
6. Findlow, J. et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51, 1127-1137 (2010).
7. Fletcher, L. D. et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72, 2088-2100 (2004). (Pubitemid 38419922)
8. Frasch, C. E., Borrow, R. & Donnelly, J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 27 Suppl 2, B112-116 (2009).
9. Borrow, R., Balmer, P. & Miller, E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 23, 2222-2227 (2005). (Pubitemid 40341456)
10. Granoff, D. M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine. 27 Suppl 2, B117-125 (2009).
11. Murphy, E. et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200, 379-389 (2009).
12. Masignani, V. et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197, 789-799 (2003). (Pubitemid 36350873)
13. Beernink, P. T. & Granoff, D. M. The modular architecture of meningococcal factor H-binding protein. Microbiology. 155, 2873-2883 (2009).
14. Beernink, P. T. & Granoff, D. M. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect. Immun. 76, 2568-2575 (2008).
15. Welsch, J. A., Rossi, R., Comanducci, M. & Granoff, D. M. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172, 5606-5615 (2004). (Pubitemid 38542063)
16. Beernink, P. T. et al. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect. Immun. 76, 4232-4240 (2008).
17. Beernink, P. T. et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186, 3606-3614 (2011).
18. Pajon, R., Beernink, P. T., Harrison, L. H. & Granoff, D. M. Frequency of factor Hbinding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 28, 2122-2129 (2010).
19. Pajon, R., Fergus, A. M., Koeberling, O., Caugant, D. A. & Granoff, D. M. Meningococcal factor H binding proteins in epidemic strains from Africa: Implications for vaccine development. PLoS Negl. Trop. Dis. 5, e1302 (2011).
20. Donnelly, J. et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. U. S. A. 107, 19490-19495 (2010).
21. Jiang, H. Q. et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 28, 6086-6093 (2010).
22. Scarselli, M. et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3, 91ra62 (2011).
23. Huson, D. H. & Bryant, D. Application of phylogenetic networks in evolutionary studies. Mol. Biol. Evol. 23, 254-267 (2006). (Pubitemid 43100040)
24. Welsch, J. A., Ram, S., Koeberling, O. & Granoff, D. M. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197, 1053-1061 (2008). (Pubitemid 351590035)
25. Madico, G. et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177, 501-510 (2006). (Pubitemid 43939163)
26. Schneider, M. C. et al. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176, 7566-7575 (2006). (Pubitemid 43849060)
27. Granoff, D. M., Welsch, J. A. & Ram, S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77, 764-769 (2009).
28. Vu, D. M. et al. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect. Immun. 80, 643-650 (2012).
29. Beernink, P. T., Lopasso, C., Angiolillo, A., Felici, F. & Granoff, D. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol. Immunol. 46, 1647-1653 (2009).
30. Giuntini, S., Beernink, P. T., Reason, D. C. & Granoff, D. M. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PloS One, In press (2012).
31. Giuliani, M. M. et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Immun. 73, 1151-1160 (2005). (Pubitemid 40165775)
32. McNeil, L. K. et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 27, 3417-3421 (2009).
33. Cantini, F. et al. Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis. J. Biol. Chem. 284, 9022-9026 (2009).
34. Mascioni, A. et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem. 284, 8738-8746 (2009).
35. Schneider, M. C. et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458, 890-893 (2009).
36. Giuntini, S., Reason, D. C. & Granoff, D. M. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79, 3751-3759 (2011).
37. Scarselli, M. et al. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J. Mol. Biol. 386, 97-108 (2009).
38. Gasteiger, J. Chemoinformatics: a new field with a long tradition. Anal. Bioanal. Chem. 384, 57-64 (2006). (Pubitemid 41817843)
39. Chao, G., Cochran, J. R. & Wittrup, K. D. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J. Mol. Biol. 342, 539-550 (2004). (Pubitemid 39149757)
40. Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557 (1997). (Pubitemid 27251573)
41. Granoff, D. M. et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160, 5028-5036 (1998). (Pubitemid 28215339)
42. Beernink, P. T. et al. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195, 1472-1479 (2007). (Pubitemid 46717465)